Alternatives for managing patients with newly diagnosed immune thrombocytopenia: a narrative review.
Expert Rev Hematol
; 15(6): 493-501, 2022 06.
Article
in English
| MEDLINE | ID: covidwho-1864902
ABSTRACT
INTRODUCTION:
Primary immune thrombocytopenia (ITP) is an acquired bleeding disorder. Conventionally, first-line ITP therapy aims to obtain a rapid response and stop or decrease the risk of bleeding by increasing the platelet count. At this point, the duration of the response, the tolerability, and the long-term safety of pharmacologic interventions are considered less of a priority. Combination treatments that simultaneously address multiple disease mechanisms are an attractive strategy to increase efficacy in acute ITP therapy. In this review, we discuss the treatment of newly diagnosed ITP patients, emphasizing the use of new combinations to benefit from their synergy. AREAS COVERED This article summarizes conventional treatment, recent and novel combinations, and COVID-19 management recommendations of newly diagnosed ITP patients. EXPERT OPINION The key areas for improvement consider the long-term effects of conventional first-line therapy, reducing relapse rates, and extending responses to achieve long-term remission. Although corticosteroids remain a first-line therapy, restricting their use to avoid toxicity and the increasing use of rituximab and TPO-RAs in the first three months after diagnosis open the landscape for future interventions in frontline therapy for ITP. First-line therapy intensification or synergistic drug combination offers a potential and realistic shift in future treatment guidelines.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Thrombocytopenia
/
Purpura, Thrombocytopenic, Idiopathic
/
COVID-19
Type of study:
Prognostic study
/
Reviews
Limits:
Humans
Language:
English
Journal:
Expert Rev Hematol
Journal subject:
Hematology
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS